CORRECTING AND REPLACING -- EDAP to Present at Rodman & Renshaw Annual Global Investment Conference, 15th Annual Healthcare C...
August 26 2013 - 9:53AM
In a release issued under the same headline earlier today by EDAP
TMS SA (Nasdaq:EDAP), please note that the presentation time should
be 10:50 am ET – 11:15 am ET, rather than 10:25 am ET – 10:50 am ET
as originally stated. The corrected release follows:
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today that Marc Oczachowski, Chief Executive
Officer, and Eric Soyer, Chief Financial Officer, are scheduled to
present at the Rodman & Renshaw Annual Global Investment
Conference that will be held in New York City from September 8 to
10, 2013.
Event: |
Rodman & Renshaw Annual Global Investment
Conference |
Presentation Date: |
Monday, September 09, 2013 |
Presentation Time: |
10:50 am ET – 11:15 am ET |
A live Web cast of the presentation will be available on EDAP's
Web site at http://investor.edap-tms.com/events.cfm. Replay of the
Web cast will be available for 30 days after the date of the
presentation.
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) treatment of localized prostate cancer. HIFU
treatment is shown to be a minimally invasive and effective
treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized
prostate cancer (stages T1-T2) who are not candidates for surgery
or who prefer an alternative option, or for patients who failed
radiotherapy treatment. Ablatherm-HIFU is approved and
commercialized in Europe as a treatment for prostate cancer and is
currently under regulatory review in the U.S. following submission
of the Pre-Market Approval Application in February 2013 after the
completion of a multi-center U.S. Phase II/III clinical trial under
an Investigational Device Exemption (IDE) granted by the FDA. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment (the Sonolith® range)
for treatment of urinary tract stones using extra-corporeal
shockwave lithotripsy (ESWL). For more information on the Company,
please visit http://www.edap-tms.com and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements that involve risks and
uncertainties. Such statements are based on management's current
expectations and are subject to a number of uncertainties,
including the uncertainties of the FDA PMA review process, our
ability to expand our U.S. operations and execute our growth
strategy and the market potential for our medical technologies, as
well as risks that could cause actual results to differ materially
from those described in these forward-looking statements. Factors
that may cause such a difference include, but are not limited to,
those described in the Company's filings with the Securities and
Exchange Commission and in particular, in the sections "Cautionary
Statement on Forward-Looking Information" and "Risk Factors" in the
Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is
in clinical trials, but not FDA-approved or marketed in the United
States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024